Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

NCT01800630 is registered in ClinicalTrials.gov with InnoPharmax Inc. as lead sponsor.

NCT NCT01800630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01800630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Lead sponsor
InnoPharmax Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
March 31, 2016
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies, malignant lymphomas